

Consensus or Controversy? Clinical Investigator Perspectives on the Current and Future Management of Hepatocellular Carcinoma and Pancreatic Cancer**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. What was reported with regard to progression-free survival (PFS) and overall survival (OS) in the COSMIC-312 trial evaluating cabozantinib with atezolizumab versus sorafenib monotherapy for patients with advanced hepatocellular carcinoma (HCC) who had not received previous systemic anticancer therapy in the advanced HCC setting?**
 - Significant improvement in only OS with cabozantinib/atezolizumab
 - Significant improvement in only PFS with cabozantinib/atezolizumab**
 - Significant improvement in both PFS and OS with cabozantinib/atezolizumab
- 2. What was the 5-year OS outcome with gemcitabine/*nab* paclitaxel in the Phase III AFACT trial comparing that combination to gemcitabine alone for surgically resected pancreatic cancer?**
 - Improvement**
 - No improvement
- 3. The POLO trial, investigating maintenance therapy with olaparib versus placebo for patients with metastatic pancreatic cancer who had a germline BRCA mutation, demonstrated which of the following outcomes with olaparib?**
 - Statistically significant improvement in OS only
 - Statistically significant improvement in PFS only**
 - Statistically significant improvement in both PFS and OS
- 4. Pemigatinib was approved by the FDA for patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma who have which of the following alterations?**
 - BRCA1/2 mutation
 - ATM mutation
 - FGFR2 fusion or rearrangement**